Showing 3331-3340 of 8741 results for "".
- New Intervention Boosts Sunscreen Usehttps://practicaldermatology.com/news/new-intervention-boosts-sunscreen-use/2467338/New research puts forth a potential approach for promoting sunscreen use to combat the persistent prevalence of skin cancer. "While the risks of not wearing sunscreen are well-documented, there are no effective interventions to promote sunscreen use across populations, and existing interv
- England's NICE Recommends Lebrikizumab for Moderate-to-Severe ADhttps://practicaldermatology.com/news/englands-nice-recommends-lebrikizumab-moderate-severe-ad/2467289/England’s National Institute for Health and Care Excellence (NICE) has recommended lebrikizumab for use in treating moderate-to-severe atopic dermatitis, Almirall S.A. announced in a press release. Lebrikizumab, sold by Almirall under the brand name Ebglyss, is indicated for the treatment
- NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe AD in the NHS Englandhttps://practicaldermatology.com/news/nice-recommends-ebglyss-lebrikizumab-use-moderate-severe-ad-nhs-england/2467288/Almirall announced that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England. Lebrikizumab is indicated for the treatment of adult and adolescent patients (12 years and older
- Almirall Announces New Sustainability Strategyhttps://practicaldermatology.com/news/almirall-announces-new-sustainability-strategy/2467252/The five pillars of Planet, People, Patients, Partners, and Principles are at the center of Almirall S.A.’s new sustainability strategy, Act4Impact 2030, the company announced. The updated strategy aims at transforming the company’s sustainability roadmap and consists of 20 strategic lines
- NEA Study Illuminates Gaps in Mental Health Help for Eczema Patientshttps://practicaldermatology.com/news/nea-study-illuminates-gaps-mental-health-help-eczema-patients/2467195/Forty-two percent of patients with atopic dermatitis (eczema) and caregivers of children/teens with the condition never spoke about mental health with primary eczema care providers, according to National Eczema Association (NEA
- Biofrontera Unveils New Red-Light-Emitting Lamp for PDT on Actinic Keratoseshttps://practicaldermatology.com/news/biofronters-unveils-new-red-light-emitting-lamp-pdt-actinic-keratoses/2467140/Biofrontera Inc. announced the launch of the RhodoLED XL, a new red-light-emitting LED lamp approved by the US Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy of actinic keratoses of mild-to-moderate sever
- Vyne Therapeutics Doses First Patient in Phase 2b Vitiligo Trial of Novel BET Inhibitorhttps://practicaldermatology.com/news/vyne-therapeutics-doses-first-patient-phase-2b-vitiligo-trial-novel-bet-inhibitor/2467132/Vyne Therapeutics announced that the first subject has been dosed in a phase 2b trial evaluating VYN201 in subjects with either active or stable nonsegmental vitiligo. VYN201 is a novel pan-bromodomain and extra-terminal domain (BET) inhibitor designed for local administration. Topline data from
- Study IDs New Potential Targets for Rare Complication of Melanomahttps://practicaldermatology.com/news/study-ids-new-potential-targets-rare-complication-melanoma/2467090/New research from the Moffitt Cancer Center may have uncovered new therapeutic targets for leptomeningeal metastasis (LMD) in melanoma, a severe complication affecting 5%-8% of melanoma patients.
- New siRNA Therapy for Benign Lesions Could Reduce Risk for Future Cancerhttps://practicaldermatology.com/news/new-sirna-therapy-benign-lesions-precursor-cancer/2467089/Researchers have developed a novel genetic therapy for reversing the formation of giant moles in patients with congenital melanocytic naevus syndrome (CMN), thereby also reducing their risk for developing melanoma later on. The therapy for this rare condition works by suppressing the NRAS
- Survey: 43% With Acne Worry They'll Never Have Clear Skinhttps://practicaldermatology.com/news/survey-43-acne-worry-theyll-never-have-clear-skin/2467063/Ninety percent of acne sufferers experience daily insecurities related to their acne, and 43% worry they will never have clear skin, according to a new survey conducted by Cutera, Inc. June is Acne Awareness Month, and Cutera said in a press release that the findings of the survey “highli